AI Article Synopsis

  • The study investigates the autoinhibitory mechanisms of the gamma-subunit of phosphorylase kinase, identifying specific inhibitory regions within its C-terminal region.
  • The removal of these inhibitory domains results in a continuously active form of the enzyme that does not require calmodulin, highlighting their essential role in regulation.
  • Two synthetic peptides associated with calmodulin binding were found to competitively inhibit this active form, revealing that these regions overlap with the autoinhibitory domains and likely modulate enzyme function.

Article Abstract

Using site-directed mutagenesis, we proposed that an autoinhibitory domain(s) is located at the C-terminal region (301-386) of the phosphorylase kinase gamma-subunit (Huang, C.-Y.F., Yuan C.-J., Livanova, N.B., and Graves, D.J. (1993) Mol. Cell. Biochem. 127/128, 7-18). Removal of the putative inhibitory domain(s) by truncation results in the generation of a constitutively active and calmodulin-independent form, gamma 1-300. To probe the structural basis of autoinhibition of gamma-subunit activity, two synthetic peptides, PhK13 (gamma 303-327) and PhK5 (gamma 343-367), corresponding to the two calmodulin-binding regions, were assayed for their ability to inhibit gamma 1-300. Competitive inhibition of gamma 1-300 by PhK13 was found versus phosphorylase b (Ki = 1.8 microM) and noncompetitive inhibition versus ATP. PhK5 showed noncompetitive inhibition with respect to both phosphorylase b and ATP. Calmodulin released the inhibition caused by both peptides. These results indicate that there are two distinct auto-inhibitory domains within the C terminus of the gamma-subunit and that these two domains overlap with the calmodulin-binding regions. Two mutant forms of gamma 1-300, E111K and E154R, were used to probe the enzyme-substrate-binding region using peptide substrate analogs corresponding to residues 9-18 of phosphorylase b (KRK11Q12ISVRGL). The data suggest that Glu111 interacts with the P-3 position of the substrate (Lys11) and Glu154 interacts with the P-2 site (Gln12). Both E111K and E154R were competitively inhibited with respect to phosphorylase b by PhK13, with 14- and 8-fold higher Ki values, respectively, than that observed with the wild-type enzyme. These data are consistent with a model for the regulation of the gamma-subunit of phosphorylase kinase in which PhK13 acts as a competitive pseudosubstrate that directly binds the substrate binding site of the gamma-subunit (Glu111 and Glu154).

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.270.13.7183DOI Listing

Publication Analysis

Top Keywords

gamma 1-300
16
phosphorylase kinase
12
kinase gamma-subunit
8
calmodulin-binding regions
8
noncompetitive inhibition
8
respect phosphorylase
8
e111k e154r
8
phosphorylase
7
gamma-subunit
6
gamma
6

Similar Publications

Spatial prediction modulates the rhythm of attentional sampling.

Cereb Cortex

September 2024

Institute of Cognitive Neuroscience, National Central University, No. 300, Jhongda Rd, Jhongli District, Taoyuan City 320, Taiwan.

Recent studies demonstrate that behavioral performance during visual spatial attention fluctuates at theta (4 to 8 Hz) and alpha (8 to 16 Hz) frequencies, linked to phase-amplitude coupling of neural oscillations within the visual and attentional system depending on task demands. To investigate the influence of prior spatial prediction, we employed an adaptive discrimination task with variable cue-target onset asynchronies (300 to 1,300 ms) and different cue validity (100% & 50%). We recorded electroencephalography concurrently and adopted adaptive electroencephalography data analytical methods, namely, Holo-Holo-Hilbert spectral analysis and Holo-Hilbert cross-frequency phase clustering.

View Article and Find Full Text PDF

Associations of Valproate Doses With Weight Gain in Adult Psychiatric Patients: A 1-Year Prospective Cohort Study.

J Clin Psychiatry

March 2024

Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.

The aim of this study was to evaluate valproate dose association with weight change, blood glucose, lipid levels, and blood pressure in a psychiatric population. Data from 215 patients taking valproate for up to 1 year were collected from 2 longitudinal studies that monitored metabolic variables between 2007 and 2022. Linear mixed-effect models and logistic regressions were used to analyze the associations between valproate doses and metabolic outcomes.

View Article and Find Full Text PDF

A suite of analytical techniques was used to obtain a comprehensive picture of per- and polyfluoroalkyl substances (PFAS) in selected Canadian food packaging used for fast foods ( = 42). Particle-induced gamma ray emission spectroscopy revealed that 55% of the samples contained <3580, 19% contained 3580-10 800, and 26% > 10 800 μg F/m. The highest total F (1 010 000-1 300 000 μg F/m) was measured in molded "compostable" bowls.

View Article and Find Full Text PDF

Characteristics and Outcomes of Anti-interferon Gamma Antibody-Associated Adult Onset Immunodeficiency.

J Clin Immunol

October 2023

Department of General Internal Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, NO.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.

Purpose: Anti-interferon gamma antibody (AIGA) is a rare cause of adult onset immunodeficiency, leading to severe disseminated opportunistic infections with varying outcomes. We aimed to summarize the disease characteristics and to explore factors associated with disease outcome.

Methods: A systematic literature review of AIGA associated disease was conducted.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!